However, to comprehensively evaluate the potential risks of cancer and infection related to prolonged use of IL-17 inhibitors and IL-23 inhibitors in individuals with psoriasis, larger, long-term, prospective cohort studies will be required. The gene discussed is IL17A; the disease is psoriasis.